Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

New Active Substance Launches Declined Again In 2016

Executive Summary

2016 witnessed a second straight year of decline in the number of new active substance launches worldwide, but trend data show that this hard measure of R&D productivity was still healthy compared with industry's performance during the first decade of the century.

Advertisement

Related Content

Novel US FDA Approvals Could Rebound In 2017: 40+ Candidates Already Under Review
NEW ACTIVE SUBSTANCES: 2014 broke records for new drug launches

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel